# A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

> **NCT06203002** · PHASE2 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 496 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** Placebo (blinded)
- **DRUG:** LX9211 (blinded)

## Key facts

- **NCT ID:** NCT06203002
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-29
- **Primary completion:** 2025-01-14
- **Final completion:** 2025-02-24
- **Target enrollment:** 496 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06203002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06203002, "A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06203002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*